Cargando…

Theoretical design of a new chimeric protein for the treatment of breast cancer

p28 and NRC peptides are two anticancer peptides with various mechanisms have shown to be effective against breast cancer. Therefore, it seems that construction of a chimeric protein containing the two peptides might cause synergistic cytotoxic effects. However, since the two peptides bear opposite...

Descripción completa

Detalles Bibliográficos
Autores principales: Soleimani, Meysam, Mahnam, Karim, Mirmohammad-Sadeghi, Hamid, Sadeghi-Aliabadi, Hojjat, Jahanian-Najafabadi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962299/
https://www.ncbi.nlm.nih.gov/pubmed/27499788
_version_ 1782444808324775936
author Soleimani, Meysam
Mahnam, Karim
Mirmohammad-Sadeghi, Hamid
Sadeghi-Aliabadi, Hojjat
Jahanian-Najafabadi, Ali
author_facet Soleimani, Meysam
Mahnam, Karim
Mirmohammad-Sadeghi, Hamid
Sadeghi-Aliabadi, Hojjat
Jahanian-Najafabadi, Ali
author_sort Soleimani, Meysam
collection PubMed
description p28 and NRC peptides are two anticancer peptides with various mechanisms have shown to be effective against breast cancer. Therefore, it seems that construction of a chimeric protein containing the two peptides might cause synergistic cytotoxic effects. However, since the two peptides bear opposite charges, production of a chimeric protein in which the two moieties do not intervene each other is difficult. In this study, our goal was to find a suitable peptide linker for the new chimeric protein in a manner that none of the peptides intervene the other’s function. We selected some linkers with different characteristics and lengths and created a small library of the chimeric proteins harboring these linkers. Homology modeling and molecular dynamic simulation revealed that (PA)(5)P and (EAAAK)(3) linkers can separate the p28 and NRC peptides effectively. Thus, the chimeric protein linked with (PA)(5)P or (EAAAK)(3) linkers might show synergistic and stronger anticancer effects than the separate peptide moieties because they could exert their cytotoxic effects freely which is not influenced by the other part.
format Online
Article
Text
id pubmed-4962299
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-49622992016-08-05 Theoretical design of a new chimeric protein for the treatment of breast cancer Soleimani, Meysam Mahnam, Karim Mirmohammad-Sadeghi, Hamid Sadeghi-Aliabadi, Hojjat Jahanian-Najafabadi, Ali Res Pharm Sci Original Article p28 and NRC peptides are two anticancer peptides with various mechanisms have shown to be effective against breast cancer. Therefore, it seems that construction of a chimeric protein containing the two peptides might cause synergistic cytotoxic effects. However, since the two peptides bear opposite charges, production of a chimeric protein in which the two moieties do not intervene each other is difficult. In this study, our goal was to find a suitable peptide linker for the new chimeric protein in a manner that none of the peptides intervene the other’s function. We selected some linkers with different characteristics and lengths and created a small library of the chimeric proteins harboring these linkers. Homology modeling and molecular dynamic simulation revealed that (PA)(5)P and (EAAAK)(3) linkers can separate the p28 and NRC peptides effectively. Thus, the chimeric protein linked with (PA)(5)P or (EAAAK)(3) linkers might show synergistic and stronger anticancer effects than the separate peptide moieties because they could exert their cytotoxic effects freely which is not influenced by the other part. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4962299/ /pubmed/27499788 Text en Copyright: © Research in Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Soleimani, Meysam
Mahnam, Karim
Mirmohammad-Sadeghi, Hamid
Sadeghi-Aliabadi, Hojjat
Jahanian-Najafabadi, Ali
Theoretical design of a new chimeric protein for the treatment of breast cancer
title Theoretical design of a new chimeric protein for the treatment of breast cancer
title_full Theoretical design of a new chimeric protein for the treatment of breast cancer
title_fullStr Theoretical design of a new chimeric protein for the treatment of breast cancer
title_full_unstemmed Theoretical design of a new chimeric protein for the treatment of breast cancer
title_short Theoretical design of a new chimeric protein for the treatment of breast cancer
title_sort theoretical design of a new chimeric protein for the treatment of breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962299/
https://www.ncbi.nlm.nih.gov/pubmed/27499788
work_keys_str_mv AT soleimanimeysam theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer
AT mahnamkarim theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer
AT mirmohammadsadeghihamid theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer
AT sadeghialiabadihojjat theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer
AT jahaniannajafabadiali theoreticaldesignofanewchimericproteinforthetreatmentofbreastcancer